Millennium Pharmaceuticals, Inc. - PowerPoint PPT Presentation

About This Presentation
Title:

Millennium Pharmaceuticals, Inc.

Description:

How have they done? Become an integrated pharmaceutical firm: Simply put they ... Market cap of ~$3 Billion 2002 expected sales of $300 Million Second ... – PowerPoint PPT presentation

Number of Views:18
Avg rating:3.0/5.0
Slides: 13
Provided by: clarkClar
Category:

less

Transcript and Presenter's Notes

Title: Millennium Pharmaceuticals, Inc.


1
Millennium Pharmaceuticals, Inc.
  • What happened next?

2
Should they do the deal?
  • Yes, because
  • Long-term revenues (220 MM plus)
  • Firm growth (1000 to 1300 employees)
  • Further commitment to agribusinesss
  • Software development and documentation

3
Should they do the deal?
  • No, because
  • 1000 employee threshold
  • Already spread thin
  • Agribusiness is not the long term goal
  • Lundbergs lack of preparation raises commitment
    and understanding concerns

4
Should they do the deal?
5
Did they do the deal?
  • No, they did not.
  • Review of the Millennium website indicates that
    they have not done any agribusiness deals since
    Monsanto.

6
Millennium strategic direction
  • Speed drug development through technology
  • Serial steps in parallel
  • Front load the discovery process
  • Strategic alliances
  • Become an integrated pharmaceutical firm

7
How have they done?
  • Speed the process
  • According to an article from TheStreet.com (July
    17, 2002), to date, Millennium has only one
    internally developed drug, an experimental
    metabolic drug in early Phase I testing, in
    clinical trials.

8
How have they done?
  • Strategic alliances
  • Since the Bayer deal, Millennium has successfully
    completed eight (8) major strategic alliances.
  • These alliances have covered a variety of
    strategic areas, to help Millennium internalize
    new skills.
  • In addition to the alliances, they have completed
    at least one major acquisition, Cor Therapeutics.

9
How have they done?
  • Become an integrated pharmaceutical firm
  • Simply put they have not. Their current
    revenue leading drug Integrilin came as part
    of the Cor Therapeutics acquisition and is
    marketed in conjunction with Schering-Plough.

10
How have they done financially?
  • Market cap of 3 Billion
  • 2002 expected sales of 300 Million
  • Second quarter loss (excluding charges and gains)
    0.16 / share vs. 0.19 (analyst expected)
  • Drug pipeline Viable and growing
    TheStreet.com July 17, 2002

11
How have they done financially?
12
Core Competencies(then now)
  • Platform
  • Productivity Innitiative
  • Mergers and Alliances
  • Franchise Areas
  • People
  • Source Millennium.com July 31, 2002
Write a Comment
User Comments (0)
About PowerShow.com